Immix Biopharma, Inc. (IMMX)Healthcare | Biotechnology | Los Angeles, United States | NasdaqCM
13.94 USD
-0.37
(-2.586%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 13.82 -0.12 (-0.120%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:12 a.m. EDT
The investment case for Immix Biopharma is currently fractured by severe fundamental distress and legal turmoil. The company is burning through cash with negative free cash flow and negative returns on equity, while facing a crisis of governance highlighted by the arrest of its Chief Medical Officer and subsequent investor lawsuits. Although the balance sheet appears robust on paper due to low debt, the operational reality suggests a potential value trap where the business model is under threat. The recent price action shows a modest recovery from multi-year lows, but this is likely a technical bounce off oversold levels rather than a reversal of the underlying trend. The disconnect between the 'strong buy' analyst consensus and the deteriorating operational news creates significant risk; investors are likely buying the dip on hopes of a turnaround, but the legal and executive instability makes this a precarious bet. For now, the security lacks the fundamental clarity required for a long-term hold. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.168533 |
| AutoARIMA | 0.168537 |
| MSTL | 0.170353 |
| AutoTheta | 0.209848 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 2.35 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.586 |
| Excess Kurtosis | -0.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.438 |
| Market Cap | 992,387,904 |
| Forward P/E | -15.42 |
| Beta | 0.11 |
| Website | https://www.immixbio.com |
As of Aug. 22, 2026, 5:12 a.m. EDT: Speculators are positioning defensively with heavy put volume at strikes significantly below the current price (5.0 and 7.5), indicating a fear of a sharp decline. Conversely, there is notable call volume at distant strikes (17.5 and 20.0) suggesting a speculative hope for a massive recovery, while near-term ATM call interest remains thin. Implied volatility is elevated, reflecting uncertainty rather than a clear directional consensus.
| Attribute | Value |
|---|---|
| 52 Week Change | 5.114035 |
| Address1 | 11,400 West Olympic Boulevard |
| Address2 | Suite 200 |
| All Time High | 15.1 |
| All Time Low | 0.68 |
| Ask | 17.72 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 1,685,970 |
| Average Daily Volume3 Month | 1,825,247 |
| Average Volume | 1,825,247 |
| Average Volume10Days | 1,685,970 |
| Beta | 0.111 |
| Bid | 13.93 |
| Bid Size | 1 |
| Book Value | 3.2 |
| City | Los Angeles |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.94 |
| Current Ratio | 25.134 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 14.17 |
| Day Low | 13.76 |
| Debt To Equity | 0.438 |
| Display Name | Immix Biopharma |
| Earnings Timestamp End | 1,793,995,200 |
| Earnings Timestamp Start | 1,793,995,200 |
| Ebitda | -41,484,312 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -18.468 |
| Enterprise Value | 766,152,640 |
| Eps Current Year | -0.74375 |
| Eps Forward | -0.90375 |
| Eps Trailing Twelve Months | -0.88 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 10.5846 |
| Fifty Day Average Change | 3.3553991 |
| Fifty Day Average Change Percent | 0.31700763 |
| Fifty Two Week Change Percent | 511.4035 |
| Fifty Two Week High | 15.1 |
| Fifty Two Week High Change | -1.1600008 |
| Fifty Two Week High Change Percent | -0.076821245 |
| Fifty Two Week Low | 1.94 |
| Fifty Two Week Low Change | 12.0 |
| Fifty Two Week Low Change Percent | 6.185567 |
| Fifty Two Week Range | 1.94 - 15.1 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,639,665,000,000 |
| Float Shares | 56,165,515 |
| Forward Eps | -0.90375 |
| Forward P E | -15.424619 |
| Free Cashflow | -25,388,076 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 21 |
| Fullday Change | -0.370001 |
| Fullday Change Percent | -2.58561 |
| Fullday Price | 13.82 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.17131001 |
| Held Percent Institutions | 0.78875 |
| Implied Shares Outstanding | 71,189,951 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-12-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California. |
| Long Name | Immix Biopharma, Inc. |
| Market | us_market |
| Market Cap | 992,387,904 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_417356223 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -39,917,212 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,018,016,299 |
| Number Of Analyst Opinions | 8 |
| Open | 14.06 |
| Operating Cashflow | -38,498,080 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 310 651 8041 |
| Post Market Change | -0.119999886 |
| Post Market Change Percent | -0.8608313 |
| Post Market Price | 13.82 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 14.31 |
| Price Eps Current Year | -18.742857 |
| Price Hint | 2 |
| Price To Book | 4.35625 |
| Profit Margins | 0.0 |
| Quick Ratio | 24.953 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.370001 |
| Regular Market Change Percent | -2.58561 |
| Regular Market Day High | 14.17 |
| Regular Market Day Low | 13.76 |
| Regular Market Day Range | 13.76 - 14.17 |
| Regular Market Open | 14.06 |
| Regular Market Previous Close | 14.31 |
| Regular Market Price | 13.94 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,143,437 |
| Return On Assets | -0.20518999 |
| Return On Equity | -0.3418 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 71,189,951 |
| Shares Percent Shares Out | 0.1455 |
| Shares Short | 10,357,703 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 8,501,228 |
| Short Name | Immix Biopharma, Inc. |
| Short Percent Of Float | 0.1759 |
| Short Ratio | 6.34 |
| Source Interval | 15 |
| State | CA |
| Symbol | IMMX |
| Target High Price | 27.0 |
| Target Low Price | 13.2 |
| Target Mean Price | 20.275 |
| Target Median Price | 20.0 |
| Total Cash | 232,107,152 |
| Total Cash Per Share | 3.244 |
| Total Debt | 1,001,752 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.88 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.2555 |
| Two Hundred Day Average Change | 5.6844997 |
| Two Hundred Day Average Change Percent | 0.6885712 |
| Type Disp | Equity |
| Volume | 1,143,437 |
| Website | https://www.immixbio.com |
| Zip | 90,064 |